United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - primidone (unii: 13afd7670q) (primidone - unii:13afd7670q) - primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. it may control grand mal seizures refractory to other anticonvulsant therapy. primidone is contraindicated in: 1) patients with porphyria and 2) patients who are hypersensitive to phenobarbital (see actions ).

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 100 mg - carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets and other treatment options before deciding to use diclofenac sodium extended-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation ). diclofenac sodium extended-release tablets are indicated: diclofenac sodium extended-release tablets are contraindicated in the following patients:

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - pimecrolimus (unii: 7kyv510875) (pimecrolimus - unii:7kyv510875) - pimecrolimus cream, 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. pimecrolimus cream, 1% is not indicated for use in children less than 2 years of age [see warnings and precautions (5.1), use in specific populations (8.4)] . pimecrolimus cream, 1% is contraindicated in individuals with a history of hypersensitivity to pimecrolimus or any of the components of the cream. there are no adequate and well-controlled studies with pimecrolimus cream, 1% in pregnant women. therefore, pimecrolimus cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in dermal embryofetal developmental studies, no maternal or fetal toxicity was observed up to the highest practicable doses tested, 10

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - isosorbide dinitrate (unii: ia7306519n) (isosorbide dinitrate - unii:ia7306519n) - isosorbide dinitrate tablets are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of immediate-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. isosorbide dinitrate is contraindicated in patients who are allergic to isosorbide dinitrate or any of its ingredients. do not use isosorbide dinitrate in patients who are taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), such as sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia. do not use isosorbide dinitrate in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - methazolamide (unii: w733b0s9sd) (methazolamide - unii:w733b0s9sd) - methazolamide tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. methazolamide tablets therapy is contraindicated in situations in which sodium and/or potassium serum levels are depressed, in cases of marked kidney or liver disease or dysfunction, in adrenal gland failure, and in hyperchloremic acidosis. in patients with cirrhosis, use may precipitate the development of hepatic encephalopathy. long-term administration of methazolamide is contraindicated in patients with angle-closure glaucoma, since organic closure of the angle may occur in spite of lowered intraocular pressure.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - butalbital 50 mg - butalbital and acetaminophen tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: abuse and dependence: butalbital: barbiturates may be habit-forming: tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. the lethal dose of a barbiturat

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 30 mg - diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. diltiazem hydrochloride tablets are contraindicated in:

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - ethacrynate sodium (unii: k41myv7mpm) (ethacrynic acid - unii:m5dp350vzv) - ethacrynic acid 50 mg in 50 ml - ethacrynic acid is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. - treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. - short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. - short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. - intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. all diuretics, including ethacrynic acid, are contraindicated in anuria. if increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued. in a few patients this diuretic has produced severe, watery diarrhea. if

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - metronidazole 7.5 mg in 1 g - metronidazole vaginal gel is indicated in the treatment of bacterial vaginosis (formerly referred to as haemophilus vaginitis, gardnerella vaginitis, nonspecific vaginitis, corynebacterium vaginitis, or anaerobic vaginosis). other pathogens commonly associated with vulvovaginitis, e.g., trichomonas vaginalis, chlamydia trachomatis, n. gonorrhoeae, candida albicans , and herpes simplex virus should be ruled out. metronidazole vaginal gel is contraindicated in patients with a prior history of hypersensitivity to metronidazole, parabens, other ingredients of the formulation, or other nitroimidazole derivatives.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin phosphate topical gel is indicated for topical application in the treatment of acne vulgaris. in view of the potential for diarrhea, bloody diarrhea, and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see contraindications, warnings, and adverse reactions). clindamycin phosphate topical gel is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.